TYRA
Company Description
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (119.95M) | (86.48M) | (69.13M) | (55.33M) | (26.29M) | (9.31M) | (4.06M) |
| EPS | -2.01 | -1.51 | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Free Cash Flow | (95.28M) | (70.44M) | (50.91M) | (50.84M) | (24.41M) | (8.07M) | (2.64M) |
| FCF / Share | -1.60 | -1.23 | -1.19 | -1.21 | -0.59 | -0.19 | -0.06 |
| Operating CF | (95.14M) | (69.77M) | (50.14M) | (50.28M) | (23.75M) | (7.76M) | (2.62M) |
| Total Assets | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M | 16.01M | 528,000 |
| Total Debt | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M | 142,000 | 253,000 |
| Cash & Equiv | 77.39M | 91.97M | 58.01M | 251.21M | 302.18M | 15.22M | 108,000 |
| Book Value | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M | (13.64M) | (4.74M) |
| Return on Equity | -0.46 | -0.25 | -0.34 | -0.21 | -0.09 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (45.56M) | (39.30M) | (33.83M) | (29.87M) | (28.10M) | (28.15M) | (25.57M) | (24.02M) | (18.70M) | (18.19M) | (22.83M) | (21.15M) |
| EPS | -0.69 | -0.64 | -0.57 | -0.50 | -0.47 | -0.47 | -0.43 | -0.41 | -0.32 | -0.35 | -0.53 | -0.49 |
| Free Cash Flow | (31.14M) | (32.66M) | (23.68M) | (22.42M) | (23.71M) | (25.47M) | (19.60M) | (17.95M) | (10.73M) | (22.16M) | (14.13M) | (17.23M) |
| FCF / Share | -0.47 | -0.53 | -0.40 | -0.38 | -0.40 | -0.43 | -0.33 | -0.30 | -0.18 | -0.42 | -0.33 | -0.40 |
| Operating CF | (31.08M) | (32.57M) | (23.62M) | (22.38M) | (23.68M) | (25.46M) | (19.59M) | (17.90M) | (10.26M) | (22.03M) | (13.53M) | (17.14M) |
| Total Assets | 383.36M | 412.04M | 282.61M | 301.85M | 321.50M | 343.48M | 363.56M | 380.59M | 392.46M | 404.74M | 225.86M | 238.36M |
| Total Debt | 5.58M | 5.70M | 5.81M | 5.92M | 6.02M | 6.12M | 6.22M | 6.32M | 6.40M | 6.49M | 6.50M | 6.11M |
| Cash & Equiv | 73.83M | 84.95M | 77.39M | 61.95M | 98.49M | 100.72M | 91.97M | 103.89M | 99.49M | 254.37M | 58.01M | 215.65M |
| Book Value | 353.66M | 387.57M | 259.18M | 280.51M | 302.15M | 323.53M | 343.15M | 362.29M | 376.04M | 389.88M | 204.26M | 222.17M |
| Return on Equity | -0.13 | -0.10 | -0.13 | -0.11 | -0.09 | -0.09 | -0.07 | -0.07 | -0.05 | -0.05 | -0.11 | -0.10 |
